Repligen Corporation Stock News

Pluristem's (PSTI) phase II studies evaluating PLX-PAD cells for treating acute respiratory distress syndrome associated with COVID-19 fail to achieve the primary endpoint.

Goldman Sachs, GameStop, Repligen, Sarepta Therapeutics and BeiGene highlighted as Zacks Bull and Bear of the Day

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

ChemoCentryx's (CCXI) Tavneos gives a significant boost to the company, following its FDA approval in ANCA-associated vasculitis. The drug is also being evaluated in other indications.

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

Biogen (BIIB) receives a fast track designation from the FDA for lecanemab to treat Alzheimer's disease.

SVB Leerink restated their buy rating on shares of Repligen (NASDAQ:RGEN) in a report published on Monday, Analyst Ratings Network reports. Several other brokerages have also commented on RGEN. KeyCorp raised their price objective on Repligen from $255.00 to $335.00 and gave the company an overweight rating in a research report on Friday, September 17th. []

The FDA accepts and grants priority review to AstraZeneca's (AZN) sBLA for Ultomiris for treating adults with generalized myasthenia gravis. A decision is expected in the second quarter of 2022.

Eli Lilly's (LLY) pivotal phase III study on lebrikizumab in combination with topical corticosteroids meets the primary and key secondary endpoints.

Sanofi (SNY) inks a deal to acquire privately-held Amunix Pharmaceuticals, which will add potentially transformative cancer therapies to its immuno-oncology pipeline.

WCM Investment Management LLC grew its stake in Repligen Co. (NASDAQ:RGEN) by 1,982.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,310,612 shares of the biotechnology companys stock after purchasing an additional 1,247,690 shares during the period. Repligen makes up about 0.9% []

Repligen (RGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Stocks Analysis by Zacks Investment Research covering: Novavax Inc, Repligen Corporation, GlaxoSmithKline PLC ADR, IVERIC bio Inc. Read Zacks Investment Research''s latest article on Investing.com

Pfizer (PFE) and BioNTech (BNTX) to evaluate a third, 3 ug dose at least two months after the second dose of Comirnaty in children aged six months to five years for better protection against COVID-19.

bluebird's (BLUE) filing for eli-cel, a gene-therapy to treat cerebral adrenoleukodystrophy, gets priority review from the FDA.